BSX vs ABT
BSX and ABT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BSXBOSTON SCIENTIFIC CORP | ABTABBOTT LABORATORIES |
|---|---|---|
| Market cap | $68.67B | $189.22B |
| P/E (TTM) | 19.3 | 30.4 |
| P/B | 2.66 | 3.63 |
| P/S | 3.4x | 4.2x |
| Dividend yield | — | 2.18% |
| Revenue | $20.61B(TTM) | $45.13B(TTM) |
| Revenue growth (YoY) | 19.9% | 5.7% |
| Net income | — | $6.28B(TTM) |
| Earnings growth (YoY) | — | -51.3% |
| EPS, diluted | $2.39(TTM) | $3.57(TTM) |
| EBIT margin | 18.0% | 18.2% |
| ROE | 0.0% | 12.5% |
| ROIC | 10.5% | 8.3% |
| 1y total return | -56.7% | -14.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BSX vs ABT
| Metric | BSX | ABT |
|---|---|---|
| End value | $25.6K | $32.5K |
| Total return | +155.9% | +224.7% |
| CAGR | +9.5% | +12.1% |
| Volatility | 27.3% | 23.9% |
| Sharpe | 0.33 | 0.43 |
| Sortino | 0.45 | 0.62 |
| Max drawdown | -60.6% | -39.6% |
Based on 2600 common trading days, 2016-03-28 → 2026-07-29 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)